DETECTION & QUANTITAION OF DRUG RESISTANT MUTANTS OF HIV

描述(改编自申请人的摘要)：众所周知 随着时间的推移，艾滋病毒的抗药性变异形式在个体中出现。因此， 甚至在开始治疗之前检查抗药性也很重要。 因此，可以确定针对特定个体的最佳药物组合。在 缺乏药物，耐药突变株的数量往往比 野生型病毒随着治疗的进展，这些幸存的病毒池中的大部分是 整合到宿主DNA中的基因。因此，监测潜伏病毒 基因组在治疗监测中是必需的。因此，非常敏感和定量 监测每一种耐药的DNA的方法 HIV-1的毒株是非常重要的。BioTraces已经开发出强大的DNA 基于定量PCR和多光子检测的诊断 技术BioTraces还开发了MPD增强的多重定量 聚合酶链式反应，它的灵敏度是几个拷贝，它可以测量相当倾斜 两个不同DNA靶标之间的比例。MPD增强型开发 提出了监测耐药HIV-1毒株的技术。 建议的商业应用：不可用

DESCRIPTION (Adapted from the Applicant's Abstract): It is well known that drug-resistant mutant forms of HIV arise in individuals over time. Therefore, it is important to check for drug-resistance even before initiating treatments so the best drug combination for a given individual can be determined. In the absence of drug, drug-resistant mutants are often much less abundant than wild-type virus. As treatment progresses, much of this surviving virus pool is that which is integrated into the host DNA. Thus, monitoring for latent viral genomes is needed in therapy monitoring. Thus, very sensitive and quantitative methods for monitoring DNA for the presence of each and every drug resistant strain of HIV-1 are very important. BioTraces has developed powerful DNA diagnostics based on quantitative PCR assay and MultiPhoton Detection technology. BioTraces has also developed MPD enhanced multiple quantitative PCR, the sensitivity of which is a few copies, and it can measure quite skewed ratios between the two different DNA targets. Development of MPD enhanced techniques for monitoring drug resistant HIV-1 strains is proposed. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE